Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma
Authors:
- 4 April 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 61 (10) , 1190-1204
Abstract
Patients with severe eosinophilic asthma experience high risk of exacerbations and reduced quality of life. Benralizumab, a monoclonal antibody binding to IL-5 receptor α subunit, is an approved drug for its treatment. The objective was to describe clinical remission after benralizumab prescription in routine clinical practice. Retrospective multicenter study with data from four hospitals in Valencian Community (Spain) with asthma units between 2019 and 2020. Data was gathered at baseline and after 12 months. We considered clinical remission after one year if the patient remained without exacerbations and use of systemic corticosteroids and with good clinical control and normal lung function. Data from 139 patients was gathered. At 12-month follow-up, 44.1% were at clinical remission, since 84.0%, 77.5%, 51.0% and 95.5% of patients did not experience exacerbations, had total asthma control test score of ≥20, prebronchodilator FEV1 of ≥80% and did not use systemic corticosteroids. A significant reduction of long-acting muscarinic antagonists (p = 0.0001), leukotriene receptor antagonists (p = 0.0326), oral corticosteroids (p < 0.0001) and short-acting beta agonists (p = 0.0499) was observed. Baseline factors with greatest individual influence on clinical remission were employment situation, tobacco use, comorbidity number, eosinophil value, number of exacerbations, FEV1, emergency visit number, and ACT, MiniAQLQ and TAI scores. Final analysis of multiple logistic regression indicated that having baseline FEV1 value below 80% increases remission chance 9.7 times a year compared to FEV1 >80%. Clinical remission after treatment with benralizumab is achievable in a high percentage of patients with severe asthma eosinophilia not controlled in real life.Keywords
Funding Information
- AstraZeneca, Spain
This publication has 41 references indexed in Scilit:
- Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacyAllergology International, 2022
- Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with BenralizumabAdvances in Therapy, 2022
- Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 StudyAnnals of Allergy, Asthma & Immunology, 2022
- Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter StudyThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Real-World Effectiveness of Benralizumab in Severe Eosinophilic AsthmaChest, 2021
- The management of severe asthma in 2020Biochemical Pharmacology, 2020
- Long-term Systemic Corticosteroid Exposure: A Systematic Literature ReviewClinical Therapeutics, 2017
- Outcomes of childhood asthma to the age of 50 yearsJournal of Allergy and Clinical Immunology, 2014
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Development of the asthma control testJournal of Allergy and Clinical Immunology, 2004